The IC50 of compound 2 was 0.41 μM against the quiescent IMR-90 cells. Thus, compound 2 does not have an in vitro therapeutic window between proliferating and quiescent cells, indicating that the cell growth inhibitory effects observed against human cancer cells result from indiscriminant proliferation-independent cytotoxicity, rather than from inhibited proliferative processes.